Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer

Clinical Nuclear Medicine

Volumn 23, Issue 10, 1998, Pages 672-677

  Petronis, John D ^a   Regan, Fintan ^a   Lin, Ke ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

ProstaScint Imaging; Prostate Cancer

Indexed keywords

INDIUM 111 CAPROMAB PENDETIDE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR LOCALIZATION;

ABDOMINAL NEOPLASMS; ANTIBODIES, MONOCLONAL; HUMANS; INDIUM RADIOISOTOPES; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION;

EID: 0031793523     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199810000-00005     Document Type: Article

References (16)

1. Haas GP, Sakr WA: Epidemiology of prostate cancer. Cancer 47:273, 1997.
2. Metlin C: The American Cancer Society National Prostate Cancer Detection Project and National Patterns of Prostate Cancer Detection & Treatment. Cancer 47:265, 1997.
3. Burgers JK, Hinkle GH, Haseman M: Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 13:103, 1995.
4. Kahn D, Williams RD, Seldin DW, et al: Radioimmunoscintigraphy with Indium-111-labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152:1490, 1994.
5. Babaian RJ, Sayer J, Podoloff DA, et al: Radioimmunoscintigraphy of pelvic lymph nodes with Indium-111-labeled monoclonal antibody CYT-356. J Urol 152:1952, 1994.
6. Haseman MK, Reed NL, Rosenthal SA: Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen positron emission tomography and biopsy correlation. Clin Nucl Med 21:704, 1996.
7. Sodee DB, Conant R, Chalfant M, et al: Preliminary imaging results using Indium-111-labeled CYT-356 (ProstaScint) in the detection of recurrent prostate cancer. Clin Nucl Med 10:759, 1996.
8. Lopes D, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC: Immunohistochemical and pharmacological characterization of the site-specific immunoconjugate CYT-356 derived from anti-prostate monoclonal antibody. Cancer Res 50:6423, 1990.
9. Gleason PF: Histologic grading and clinical staging of prostate carcinoma. In: Tannenbaum M, ed: Urologie Pathology: The Prostate. Philadelphia, PA: Lea and Febiger, 1977:171.
10. Waxman S, Stevens AK, Walsh RA, Mackenzie SH, Crawford ED: Management of asymptomatic rising PSA after prostatectomy or radiation therapy. Oncology 11:457, 1997.
11. Silver DA, Pellicer I, Fair WR, et al: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81, 1997.
12. Alzraki NP, Eshima D, Eshima LA, et al: Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 27:55, 1997.
13. Ferrari AC, Stone NN, Eyler JN, et al: Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high risk prostate cancer. J Natl Cancer Inst 89:1498, 1997.
14. Lin K, Nagy JA, Xu H, et al: Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 54:2269, 1994.
15. Chiacchierini RP, Piantadosi S, Partin AW, et al: Logistic regression analysis combining serum PSA, Gleason score, and monoclonal antibody scan (ProstaScint) to predict lymph nodal involvement in prostate cancer (abstr). J Urol 157(suppl No 4):205, 1997.
16. Movsas B, Hanion AL, Teshima T, et al: Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer 80:1093, 1997.